@riccardo123:
1: Clin Drug Investig. 2009;29(5):283-92. doi: 10.2165/00044011-200929050-00001.
HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled, multicentre trial.
Leavitt M, Charles G, Heyman E, Michaels D.
Private Dermatology Practice, Maitland, Florida, USA.
mlleavitt@aol.com
BACKGROUND AND OBJECTIVE: The use of low levels of visible or near infrared light for reducing pain, inflammation and oedema, promoting healing of wounds, deeper tissue and nerves, and preventing tissue damage has been known for almost 40 years since the invention of lasers. The HairMax LaserComb is a hand-held Class 3R lower level laser therapy device that contains a single laser module that emulates 9 beams at a wavelength of 655 nm (+/-5%). The device uses a technique of parting the user's hair by combs that are attached to the device. This improves delivery of distributed laser light to the scalp. The combs are designed so that each of the teeth on the combs aligns with a laser beam. By aligning the teeth with the laser beams, the hair can be parted and the laser energy delivered to the scalp of the user without obstruction by the individual hairs on the scalp. The primary aim of the study was to assess the safety and effectiveness of the HairMax LaserComb laser phototherapy device in the promotion of hair growth and in the cessation of hair loss in males diagnosed with androgenetic alopecia (AGA).
METHODS: This double-blind, sham device-controlled, multicentre, 26-week trial randomized male patients with Norwood-Hamilton classes IIa-V AGA to treatment with the HairMax LaserComb or the sham device (2 : 1). The sham device used in the study was identical to the active device except that the laser light was replaced by a non-active incandescent light source.
RESULTS: Of the 110 patients who completed the study, subjects in the HairMax LaserComb treatment group exhibited a significantly greater increase in mean terminal hair density than subjects in the sham device group (p < 0.0001). Consistent with this evidence for primary effectiveness, significant improvements in overall hair regrowth were demonstrated in terms of patients' subjective assessment (p < 0.015) at 26 weeks over baseline. The HairMax LaserComb was well tolerated with no serious adverse events reported and no statistical difference in adverse effects between the study groups.
CONCLUSIONS: The results of this study suggest that the HairMax LaserComb is an effective, well tolerated and safe laser phototherapy device for the treatment of AGA in males.
PMID: 19366270 [PubMed - indexed for MEDLINE] globe by pursuing additional international medical device registrations and further establish the credibility of the HairMax LaserComb® in the global marketplace”.
FONTE: www.hairmax.com
studio approfondito e + recente: http://www.hairmax.com/Introduction/KeyClinicalStudy.aspx
studi precedenti: http://www.hairmax.com/Introduction/HairMaxResearchDevelopments.aspx
tramite google ho anche trovato questa news fresca di fine agosto!
Landmark Study on Ex-Vivo Growth of Hair Exposed to Laser PhotoTherapy
Study proves that laser energy stimulates the growth of hair ex-vivo
FOR IMMEDIATE RELEASE
PRLog (Press Release) – Aug 21, 2009 – BOCA RATON, FL – First of a kind data from a study conducted by Laboratoire Bio-EC, Paris France on the on ex-vivo growth of hair from Low Level Laser Light exposure of hair follicles maintained in Philpott hair culture medium were presented at the 17th Annual Meeting of the International Society of Hair Restoration Surgeons (ISHRS) by Dr. Michael Hamblin..
Michael Hamblin, PhD, Associate Professor, Harvard Medical School/Wellman Center for Photomedicine, Massachusetts General Hospital, is one of the foremost researchers in the field of Low Level Light Therapy (LLLT) and Photodynamic Therapy. He presented important data from this study which compared a dose of laser energy and a reference dose on the ex-vivo growth of hair to show that laser energy stimulated hair growth. Isolated follicles were placed in the Philpott hair culture medium, exposed to the laser doses, and measured for hair length increases. Analysis of hairs grown ex-vivo exposed to the two laser doses, were photographed at regular intervals over ten days.
The conclusion of the study was that the wave length dose studied induced statistically significant ex-vivo increase in hair growth vs. control dose at the conclusion of the study.
This significance of these results is that for the first time a study has documented ex-vivo hair growth in isolated hairs using laser stimulation. The results conclusively indicated that laser energy stimulated proliferation in the hair matrix. This is the first time that data has been presented at a medical conference showing positive reaction on ex-vivo hair growth from laser energy exposure.
Presentation of these findings at the ISHRS by Dr. Hamblin is further recognition of Lexington’s dedication in developing effective therapies for the prevention and treatment of hair loss.
Mr. David Michaels said, “We are honored to have had Dr. Hamblin present this important data to the premier organization of hair transplant doctors. We believe that the findings of this ex-vivo study are an important step in helping to validate the HairMax LaserComb as a key modality in the treatment of hair loss.”
fonte: http://www.prlog.org/10317683-landmark-study-on-exvivo-growth-of-hair-exposed-to-laser-phototherapy.html
mi pare siano dei buoni segni relativamente a questa terapia!
[X][X][X][X][X][X][X][X][X][^][^][^][^][^][^][^]
]